Business Wire

NY-CITI

2.11.2020 14:02:05 CET | Business Wire | Press release

Share
Citi Selected as Financial Advisor to Gavi, The Vaccine Alliance’s COVAX Facility

Citi today announced the firm has been selected by Gavi, the Vaccine Alliance, to be the financial advisor for the COVAX Facility, its global procurement mechanism for COVID-19 vaccines.

The COVAX Facility is part of COVAX , a global, multilateral initiative aimed at developing, manufacturing and deploying COVID-19 vaccines on a fair and equitable basis. It is co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) , and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organizations and others.

Citi will provide Gavi with expert advice on structures to mitigate sovereign, credit and operational risk as the COVAX Facility seeks to facilitate pooled procurement and equitable distribution of safe and effective COVID-19 vaccines from multiple pharmaceutical manufacturers to all COVAX participating economies once they reach licensure.

“Citi considers this assignment to be a clear demonstration of who we are as a firm and it builds on the work we’re doing to help combat this crisis on many fronts,” said Jane Fraser, President of Citigroup and CEO of Global Consumer Banking. “Funding of vaccines is at the core of bringing this crisis to an end, and Citi is honored to contribute to this unprecedented effort. We are bringing top talent together from around the firm to support Gavi in achieving its global objectives.”

In its first phase, and up until the end of 2021, the COVAX Facility aims to secure and deliver 2 billion doses of vaccines to be distributed to member countries’ populations. The facility currently counts over 180 sovereign government entities as participants.

In its role as advisor, Citi will advise and assist in finding risk mitigation and execution strategies in connection with the facility, including supporting the building of strategies to operationalize and maintain the COVAX Facility.

“COVAX represents the best chance to provide people in all countries with rapid, fair and equitable access to COVID-19 vaccines as soon as they become available. We’re delighted to engage Citi, allowing the COVAX Facility to benefit from expert external advice to complement our in-house expertise, supporting our essential work mitigating risk and structuring the COVAX Facility to be as effective as possible,” said Dr. Seth Berkley, Chief Executive Officer, Gavi.

Throughout the pandemic, Citi has worked closely with governments and the private sector to find liquidity alternatives and funding solutions in response to COVID-19. This has included large targeted development bank and NGO efforts for the pandemic, including COVID-19 emergency programs by the World Bank, Africa Development Bank, the New Development Bank, and Gavi’s own International Finance Facility for Immunisation (IFFIm), where Citi recently acted as joint bookrunner on its $500m vaccine bond.

“Just, rapid and efficient funding and distribution of COVID-19 vaccines remains our best hope of ending this crisis, and we are committed to optimizing the COVAX Facility for that purpose, said Jay Collins, Vice Chairman, Banking, Capital Markets and Advisory at Citi and the lead advisor for the Citi team. “The size and complexity of this facility is unprecedented, and its urgency for the world is paramount,” he continued.

“We are pleased to partner with Citi on this landmark endeavor,” said Assietou Sylla Diouf, Managing Director of Finance & Operations, Gavi. “Never has such a facility been more critical given the crisis we are currently facing. Citi’s presence in over 160 countries and jurisdictions and its expertise will help to ensure the financial mechanics of the COVAX Facility are best able to support COVAX’s ambitious goals of ending the acute phase of the pandemic by the end of 2021.”

Citi remains committed to supporting clients and community partners to help drive a positive socially and environmentally sustainable response to COVID-19. Citi and the Citi Foundation have committed more than $100 million to date in support of COVID-19-related community relief efforts globally. Citi is proud of its efforts to fund stakeholders across multiple United Nations Sustainable Development Goals (SDGs), and is particularly proud of the contribution this work with Gavi will make to SDG 3: Ensure healthy lives and promote well-being for all at all ages.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye